This evidence brief is not medical advice. It is a source-linked literature search draft for research and writing workflows. Always inspect the original papers before citing or applying any finding.
Research question
Do GLP-1 receptor agonists improve weight loss outcomes?
Short answer
The returned literature should be checked for drug, dose, follow-up duration, population, and adverse-event reporting.
Search conditions and results
- Claim searched: GLP-1 receptor agonists improve weight loss outcomes.
- Search intent: Find source-linked biomedical papers about GLP-1 receptor agonists and weight loss.
- Result set: Top source-linked biomedical papers returned by LitSource for this claim.
- Last refreshed: 2026-05-04
Top papers found
| Paper | Year | Journal | Source | Evidence snippet |
|---|---|---|---|---|
| Addressing the challenge of obesity in primary care: a review of effective interventions and implementation strategies. | 2025 | Diabetology & metabolic syndrome | PMID 40846976 | According to a 2025 retrospective cohort study, among people prescribed GLP-1 receptor agonists, active use of a digital weight management platform significantly improved weight loss outcomes (e.g., an additional 3.5% p… |
| Weight-centric prevention of cancer. | 2024 | Obesity pillars | PMID 38495815 | Newer glucagon-like peptide-1 (GLP-1) receptor agonists (i.e., semaglutide) and glucose-dependent insulinotropic polypeptide (GIP) co-agonists (i.e., tirzepatide) have showed significantly superior weight loss outcomes… |
| Digital engagement enhances dual GIP/GLP-1 receptor agonist and GLP-1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety. | 2026 | Diabetes, obesity & metabolism | PMID 41145379 | The latest landmark trials of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists, such as semaglutide and tirzepatide, have shown substantial weight-loss outcomes. |
| The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment. | 2025 | Cureus | PMID 40497223 | The recent emergence and widespread adoption of potent anti-obesity medications, particularly glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and dual incretin agonists such as tirzepatide, have creat… |
| Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study. | 2025 | Journal of medical Internet research | PMID 40164173 | This study provides compelling evidence that engagement with digital health platforms significantly enhances weight loss outcomes among individuals undergoing pharmacotherapy with GLP-1 receptor agonists for obesity man… |
| Practice Patterns in Body Mass Index Optimization Among US Arthroplasty Surgeons: Results of a National American Association of Hip and Knee Surgeons Survey. | 2026 | Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews | PMID 41706617 | A retrospective cohort study analyzed the use of Glucagon-like Peptide-1 (GLP-1) receptor agonists in 268,504 THA and 386,356 TKA patients, finding that preoperative GLP-1 use (n = 1044 for THA; n = 2095 for TKA) was as… |
| Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss. | 2024 | Obesity reviews : an official journal of the International Association for the Study of Obesity | PMID 38320760 | Glucagon-like peptide 1 (GLP-1) receptor agonists are revolutionizing obesity and type 2 diabetes treatment, delivering remarkable weight loss outcomes. |
| A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications. | 2023 | Life (Basel, Switzerland) | PMID 37109541 | In this analysis, we emphasize the six GLP-1 receptor agonists' remarkable weight loss outcomes across a range of clinical research programs. |
What the evidence appears to support
The papers above were returned by a source-linked LitSource search for this claim. Treat them as candidate evidence: inspect the highlighted snippet, then open the original paper before citing.
What remains uncertain
This draft does not rank clinical certainty, replace systematic review methods, or decide whether the claim should be used in patient care. Check study design, population, intervention details, effect size, and recency before using any citation.
Try this search in LitSource
Paste the claim into LitSource to rerun the search, inspect updated evidence snippets, and export citations.